Mr. Allen Davidoff reports

XORTX APPOINTS NEW DIRECTOR

XORTX Therapeutics Inc. has appointed Depesh Narotam to the board of directors as an independent director.

Mr. Narotam has been in the financial services industry for over 20 years. He has developed considerable expertise in debt financing, delivering strategic lending solutions to a diverse client base. Over the course of his career Mr. Narotam has developed a comprehensive understanding of various sectors specifically the real estate lending landscape where he has been responsible for market expansion and strategic partnerships to those that have benefited from enhanced market presence and long term performance.

Mr. Narotam

Mr. Narotam, age 43, was appointed as a director of the company effective July 27, 2026. The board of directors has determined that Mr. Narotam is an independent director under applicable Nasdaq listing standards and Canadian securities laws. Mr. Narotam has also been appointed to serve as a member of the compensation, governance and nominating committee of the board of directors. Mr. Narotam is a resident of British Columbia, Canada, and has served as a mortgage development manager since December, 2020, at Vancity, Canada's largest community-based credit union and a member-owned financial co-operative. Prior to joining Vancity, Mr. Narotam spent 16 years with Westminster Savings Credit Union (now Prospera Credit Union) where he held various positions in financial services including mortgage specialist and business development manager.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) the company's lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical stage program for Type 2 diabetic nephropathy and recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, the company is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.